Phase 2 topline data from Avail trial expected in Q3 2025. Topline results from the Phase 2 Avail trial of canvuparatide, a potential long-acting, once-weekly parathyroid hormone (PTH) peptide prodrug ...

A new study from researchers at the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) reveals that extremely simple peptides can mimic a biological process that protects ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies ...

Smith’s invention enabled the precise capture of light in electronic form, and has transformed science, medicine and daily ...

The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, ...

A new wave of luxury wellness facilities are catering to travelers looking to maintain their health goals alongside ...

XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and ...

Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Anal ...

This edit of wellness retreats, super supplements, and medical-grade devices, will help you feel and look your best.

LMO2 is an intrinsically disordered transcription factor activated in T cell leukaemia that is difficult to target. It forms part of a multiprotein complex that has bipartite DNA binding through ...

A string of blunders led to the value of Novo Nordisk dropping £52bn last week. Could a new weight-loss pill help it regain ...

Surge Copper Corp. (TSXV:SURG)(OTCQB:SRGXF), based in British Columbia, Canada, focused on the development of the Berg copper project, today announced that ...